Mel-CAM Antibody (OJ79c MUC 18): sc-53369

Mel-CAM Antibody (OJ79c MUC 18) is a mouse monoclonal IgG1 antibody that detects Mel-CAM in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). Mel-CAM, also known as MCAM, MUC18, or CD146, is a transmembrane glycoprotein encoded by the human Mel-CAM gene, which plays a crucial role in cell adhesion and is a member of the immunoglobulin superfamily. This protein consists of 603 amino acids, featuring a signal peptide, five immunoglobulin-like domains, a transmembrane region, and a short cytoplasmic tail, which are essential for its function. Mel-CAM is predominantly expressed in advanced primary and metastatic melanomas, as well as in neuroectodermal lineage cell lines, but is absent in normal melanocytes. Mel-CAM expression is found in approximately 80% of advanced primary human melanomas and is closely associated with the progression of metastatic disease. Mel-CAM activation triggers an outside-in signaling pathway involving protein tyrosine kinases such as Fyn, Focal Adhesion Kinase (FAK), and paxillin, which are vital for the dynamics of actin cytoskeleton rearrangement. This process is not only critical for tumor cell migration and invasion but also plays a significant role in maintaining thymic architecture and function, highlighting Mel-CAM′s importance in both cancer biology and immune system integrity.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Mel-CAM Antibody (OJ79c MUC 18) References:

1. The role of CD146 (Mel-CAM) in biology and pathology.  |  Shih, IM. 1999. J Pathol. 189: 4-11. PMID: 10451481
2. Endothelin-1 upregulates MCAM in melanocytes.  |  Mangahas, CR., et al. 2004. J Invest Dermatol. 123: 1135-9. PMID: 15610525
3. Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146.  |  Rapanotti, MC., et al. 2017. Cell Death Discov. 3: 17005. PMID: 28280601
4. MCAM contributes to the establishment of cell autonomous polarity in myogenic and chondrogenic differentiation.  |  Moreno-Fortuny, A., et al. 2017. Biol Open. 6: 1592-1601. PMID: 28923978
5. Therapeutic Targeting of CD146/MCAM Reduces Bone Metastasis in Prostate Cancer.  |  Zoni, E., et al. 2019. Mol Cancer Res. 17: 1049-1062. PMID: 30745464
6. Role of CD146 (MCAM) in Physiological and Pathological Angiogenesis-Contribution of New Antibodies for Therapy.  |  Joshkon, A., et al. 2020. Biomedicines. 8: PMID: 33352759
7. Overexpression of MCAM induced by SMYD2-H3K36me2 in breast cancer stem cell properties.  |  Li, X., et al. 2022. Breast Cancer. 29: 854-868. PMID: 35553018
8. Galectin-3 Is a Natural Binding Ligand of MCAM (CD146, MUC18) in Melanoma Cells and Their Interaction Promotes Melanoma Progression.  |  Pang, Y., et al. 2022. Biomolecules. 12: PMID: 36291660
9. Cooperative polarization of MCAM/CD146 and ERM family proteins in melanoma.  |  Miller, SG., et al. 2024. Mol Biol Cell. 35: ar31. PMID: 38117590
10. The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma.  |  Shih, LM., et al. 1997. Am J Pathol. 151: 745-51. PMID: 9284823

The preferred Mel-CAM antibody is Mel-CAM Antibody (P1H12): sc-18837.